Analysis of:
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty (content.nejm.org)
This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).
Analysis of:
New Study Probes Safety of Erythropoiesis-Stimulating Agents (www.medscape.com)
Use of Epo Stimulating Agents (ESAs) for cancer patients have all but come to a screeching halt when a plattoon of studies came out suggesting that ESAs might actually cause more harm, notably by possibly acting as a growth factor for tumor cells. Now, reserachers are trying to determine...
Analysis of:
New Study Probes Safety of Erythropoiesis-Stimulating Agents (www.medscape.com)
Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.
Analysis of:
Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
Only 1 in 5 physicians use electronic patient records. ( and those are either in University Hospitals, large multispecialty clinics or VA hospitals)
Analysis of:
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer (jco.ascopubs.org)
Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.
Analysis of:
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 (content.nejm.org)
"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...
Analysis of:
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders (bloodjournal.hematologylibrary.org)
Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.
Analysis of:
Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial (www.pipelinereview.com)
Tarnsgene's cancer vaccine TG 4010 increased response rates and progression free survival when added to chemotherapy in patients with advanced small cell lung cancer. The overall survival rates and time to progression were not much different in the 2 treatment groups. The vaccine is novel and efficacy...
Analysis of:
Tight Rein on Blood Sugar Has No Heart Benefit (www.nytimes.com)
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
Analysis of:
Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial (www.pipelinereview.com)
Transgene's TG4010 vaccine has a fairy elegant two-gene design. It appears to add benefit to a standard chemo regimen in this good-sized, randomized Phase II study for advanced lung cancer. More mature survival data will be ready by year's end. Phase III study is being planned. ...